AbbVie / Allergan
AbbVie / Allergan is the company node behind Botox, the best-known botulinum toxin type A reference brand. Allergan built the Botox franchise before AbbVie acquired Allergan, and the combined company context now anchors much of the global toxin-market conversation.
The company relationship matters because Botox is often used as shorthand for the whole category. In this index, AbbVie / Allergan connects company history, product identity, therapeutic and aesthetic labeling, and comparison limits.
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Manufacturer / company context | AbbVie ownership of the Allergan toxin franchise |
| Core toxin relationship | Established type A franchise centered on onabotulinumtoxinA; emerging type E development program |
| Main product nodes | Botox, Botox Cosmetic, and trenibotulinumtoxinE / Boey regulatory development |
| Market role | Category reference point across therapeutic and aesthetic botulinum toxin discussions |
| Comparison anchors | Dysport, Xeomin, Daxxify, Jeuveau, Letybo |
Product Portfolio Context
Section titled “Product Portfolio Context”Botox and Botox Cosmetic are the primary toxin products represented by AbbVie / Allergan in the current site structure. Their shared onabotulinumtoxinA identity should not erase the distinction between therapeutic and aesthetic label contexts.
The company’s emerging toxin portfolio also includes trenibotulinumtoxinE. On May 21, 2026, the CHMP recommended EU marketing authorisation for the proposed Boey product for glabellar lines, but the European Commission had not granted final authorisation as of June 6, 2026. In the United States, the FDA issued a Complete Response Letter for the application on April 23, 2026, so the product is not U.S.-approved.
The broad visibility of Botox creates a useful reference point for readers entering the field, but it also creates a common misread: a Botox-based assumption should not be applied automatically to another botulinum toxin product.
Market Interpretation
Section titled “Market Interpretation”AbbVie / Allergan sits at the intersection of medical neurology, aesthetics, brand recognition, and long-running category education. The company also appears in market-history discussion around the Daewoong / Evolus / Medytox dispute and settlement activity.
That history is commercially important, but it does not establish clinical superiority, unit equivalence, or interchangeability among Botox, Jeuveau, Nabota, or other toxin products.
Related People
Section titled “Related People”| Person | Relationship to this company node |
|---|---|
| Nicole Mowad-Nassar | Current Senior Vice President, AbbVie and President, Global Allergan Aesthetics. |
| Darin J. Messina, Ph.D. | Senior Vice President, Aesthetics R&D, connecting Allergan Aesthetics to neurotoxin and broader aesthetics development. |
| Carrie Strom | Former Global President of Allergan Aesthetics and the launch leader named in AbbVie’s 2020 announcement creating the dedicated aesthetics business. |
Label and Comparison Limits
Section titled “Label and Comparison Limits”Botox interpretation should stay tied to current prescribing information. Units are product-specific, approved uses differ by label and country, and the Botox name should not be used as a generic dosing or comparison standard.
Botulinum toxin type A provides the shared serotype context for Botox. Botulinum toxin type E separates trenibotulinumtoxinE’s biology and regional regulatory status from the established franchise. Botulinum toxin explains why products in the same family can still differ in assays, indications, formulation, and safety language.